Eli Lilly and Company (LLY)vsTravere Therapeutics Inc (TVTX)
LLY
Eli Lilly and Company
$1,409.27
-0.11%
HEALTHCARE · Cap: $1.26T
TVTX
Travere Therapeutics Inc
$49.41
+0.30%
HEALTHCARE · Cap: $4.77B
Smart Verdict
WallStSmart Research — data-driven comparison
Eli Lilly and Company generates 14522% more annual revenue ($86.46B vs $591.33M). LLY leads profitability with a 31.9% profit margin vs -7.3%. LLY earns a higher WallStSmart Score of 74/100 (B).
LLY
Strong Buy74
out of 100
Grade: B
TVTX
Avoid31
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for LLY.
Margin of Safety
+19.5%
Fair Value
$62.60
Current Price
$49.41
$13.19 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 79 in profit
Keeps 32 of every $100 in revenue as profit
Strong operational efficiency at 53.7%
Revenue surging 38.6% year-over-year
Generating 7.8B in free cash flow
Revenue surging 48.2% year-over-year
Areas to Watch
Elevated debt levels
Premium valuation, high expectations priced in
Trading at 31.2x book value
0.0% earnings growth
Operating margin of 2.3%
Trading at 190.0x book value
ROE of -69.4% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : LLY
The strongest argument for LLY centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 31.9% and operating margin at 53.7%. Revenue growth of 38.6% demonstrates continued momentum.
Bull Case : TVTX
The strongest argument for TVTX centers on Revenue Growth. Revenue growth of 48.2% demonstrates continued momentum.
Bear Case : LLY
The primary concerns for LLY are Debt/Equity, P/E Ratio, Price/Book. A P/E of 46.0x leaves little room for execution misses. Debt-to-equity of 1.62 is elevated, increasing financial risk.
Bear Case : TVTX
The primary concerns for TVTX are EPS Growth, Operating Margin, Price/Book. Debt-to-equity of 25.16 is elevated, increasing financial risk.
Key Dynamics to Monitor
LLY profiles as a growth stock while TVTX is a hypergrowth play — different risk/reward profiles.
TVTX carries more volatility with a beta of 1.14 — expect wider price swings.
TVTX is growing revenue faster at 48.2% — sustainability is the question.
LLY generates stronger free cash flow (7.8B), providing more financial flexibility.
Bottom Line
LLY scores higher overall (74/100 vs 31/100), backed by strong 31.9% margins and 38.6% revenue growth. TVTX offers better value entry with a 19.5% margin of safety. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Eli Lilly and Company
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries.
Visit Website →Travere Therapeutics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development and commercialization of therapies for the treatment of rare diseases. The company is headquartered in San Diego, California.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?